Evidence map›Paper›PMID 19400908›Full record

ReviewClinical and experimental allergy : journal of the British Society for Allergy and Clinical Immunology2009

Thymic stromal lymphopoietin, OX40-ligand, and interleukin-25 in allergic responses.

Y-H Wang, Y-J Liu

Open access · greenAbstract readReview
In one paragraph

Review in Clinical and experimental allergy : journal of the British Society for Allergy and Clinical Immunology, 2009. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 76 papers, 2 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
76citing papers in PubMed, 2 pooled it
15.5field-weighted citation impact, top 1% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

76 citing papers in PubMed, 2 syntheses or guidelines pooled it, 148 citations in OpenAlex.

  1. Anti-IL-5 therapies for asthma.The Cochrane database of systematic reviews · 2022
    Pooled it
  2. Anti-IL5 therapies for asthma.The Cochrane database of systematic reviews · 2017
    Pooled it
  3. Review
  4. Review
  5. CD4Frontiers in immunology · 2025
    Review
  6. Review
  7. Review
  8. Article
  9. Review
  10. Review
  11. Review
  12. Review
  13. Article
  14. ncRNAs in Type-2 Immunity.Non-coding RNA · 2020
    Review
  15. Article
  16. Article
  17. Review
  18. Review
  19. Article
  20. Article

16 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

2 authors at 1 institution in 1 country.

Y-H WangDepartment of Immunology and Center of Cancer Immunology Research, The University of Texas M. D. Anderson Cancer Center, Houston, TX 77030, USA. yui_hsi.wang@cchmc.org
Y-J Liu
The University of Texas MD Anderson Cancer Center · US

Funding

TSLP and Allergic InflammationR01AI061645 · NIAID · UNIVERSITY OF TX MD ANDERSON CAN CTR · PI LIU, YONG-JUN · 2004 to 2008
$1.8M
NIAID NIH HHS R01 AI061645
6 · The paper itself

Abstract

Allergic diseases are often triggered by environmental allergens that induce dominant type 2 immune responses, characterized by the infiltrated T-helper type 2 (TH2) lymphocytes, eosinophils, and elevated TH2 cytokines. In addition to TH2 type immune responses, epithelial stress and injury linked to tissue remodelling are often observed, suggesting that epithelial cells may play important role in regulating allergic responses. Dendritic cells (DCs), the professional antigen-presenting cells with the capabilities of sampling allergens, are considered as the key player on instructing TH2 immune responses. Whether inflamed epithelium can regulate innate immunity, such as macrophages and DCs, which in turn instructs adaptive immunity has long been hypothesized. Studies of thymic stromal lymphopoietin (TSLP), an epithelial cells-derived cytokine, that can strongly activate DCs, provide important evidences that the epithelial barrier can trigger allergic diseases by regulating immune responses. The finding that OX40/OX40Ligand (OX40L) interactions are the molecular trigger responsible for the induction and maintenance of TH2 responses by TSLP-activated DCs provides a plausible molecular explanation for TSLP-mediated allergy. Recent progresses in characterizing the pro-inflammatory IL-17 cytokine family have added an additional layer of complexity on the regulation of allergic inflammation. TSLP-DCs can induce a robust expansion of TH2 memory cells and strengthen functional attributes by up-regulating their surface expression of IL-17RB (IL-25R), the receptor for cytokine IL-17E (IL-25), a distinct member of IL-17 cytokine family. IL-17E (also known as IL-25) produced by epithelial cells, and other innate cells, such as eosinphils, basophils, and mast cells, are shown to regulate adaptive immunity by enhancing TH2 cytokine productions. These exciting findings expand our knowledge of the complex immunological cascades that result in allergic inflammation and may provide novel therapeutic approaches for the treatment of allergic diseases.

Indexed as

AnimalsCytokinesDendritic CellsEpithelial CellsHumansHypersensitivityImmunity, ActiveImmunity, InnateImmunoglobulinsInterleukin-17OX40 LigandReceptors, CytokineTh2 CellsThymic Stromal LymphopoietinCRLF2 protein, humanCytokinesImmunoglobulinsInterleukin-17OX40 LigandReceptors, CytokineThymic Stromal LymphopoietinTslpr protein, mouse

Identifiers

PMID19400908
PMCPMC2744577
OpenAlexW2109029867

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.